Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
Clinical trial NCT07318649 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07318649
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2026-12-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.